Treatment of Lennox-Gastaut Syndrome
Topiramate (TPM) and lamotrigine (LTG) should be used as adjunctive therapy to treat drop attacks and seizures in Lennox-Gastaut syndrome, with valproate remaining the first-line treatment. 1
First-Line Treatment Algorithm
Start with valproate as monotherapy for newly diagnosed LGS. 2 This remains the standard initial approach despite the absence of randomized controlled trials specifically in LGS, based on decades of clinical experience and its broad-spectrum efficacy.
Second-Line Adjunctive Therapy
If valproate monotherapy fails to control seizures:
Add lamotrigine first - Doses should be weight and valproate-adjusted:
Add rufinamide second if lamotrigine is insufficient 2
Third-Line Options
When seizure control remains suboptimal with valproate plus lamotrigine or rufinamide, consider these adjunctive options (listed alphabetically, as evidence quality is similar):
Topiramate: 6 mg/kg/day
Limit polypharmacy: Use no more than two antiseizure medications together whenever possible. 2
Medications to Avoid
Do not use gabapentin - Case reports document worsening of myoclonic seizures in LGS patients. 1 Additionally, carbamazepine has been reported to cause seizure worsening in this population. 1
Non-Pharmacological Approaches
These should be used in conjunction with (not instead of) medication therapy:
- Ketogenic diet therapies 2, 5
- Vagus nerve stimulation 2
- Corpus callosotomy 2, 5
- Resective epilepsy surgery when appropriate 5
Special Considerations
Drop attacks (tonic or atonic seizures) are the primary treatment target because they are the most dangerous seizure type, frequently causing injuries. 1 This is why reduction in drop attacks serves as the primary outcome variable in clinical trials rather than total seizure frequency.
LGS patients are uniquely prone to seizure exacerbation with certain antiseizure medications, making drug selection critical. 1 The syndrome requires broad-spectrum drugs rather than narrow-spectrum agents effective only for partial seizures.
Monitoring and Follow-Up
Patients with established LGS should be reviewed at least annually by an experienced neurologist. 2 Frequent reassessment is essential as seizure patterns, EEG findings, and cognitive/behavioral features evolve over time. 4, 6
Evidence Quality Note
The guideline recommendations are based on Class I evidence for both topiramate and lamotrigine in LGS, representing the highest quality data available. 1 These are Level A recommendations from the American Academy of Neurology and American Epilepsy Society. More recent evidence supports additional options like cannabidiol and fenfluramine, though these were not available when the original guidelines were published. 2, 3